Dermapharm's 2024 Financial Performance Exceeds Expectations

Dermapharm Holding SE reported a successful 2024 financial year, with consolidated revenue rising by 4.0% to EUR 1,180.8 million. The firm's unadjusted EBITDA increased by 10.2% to EUR 308.9 million, resulting in an unadjusted EBITDA margin of 26.2%. This exceeds the company's previous guidance, showcasing robustness in challenging market conditions.

The "Branded pharmaceuticals" segment achieved a 9.8% revenue increase to EUR 585.1 million, driven by strong growth within Germany and through internationalisation. The adjusted EBITDA for this segment stood at EUR 264.8 million, reflecting the success of strategic acquisitions and product integrations.

However, revenue from "Other healthcare products" decreased by 4.7% to EUR 354.4 million, attributed to prior sales and price adjustments in 2023 affecting 2024's financial outcomes. Meanwhile, the "Parallel import business" saw a slight revenue growth of 4.5% but faced decreased profitability.